Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Millipore Launches Eshmuno® A Media and Chromabolt™ Columns

Published: Wednesday, September 18, 2013
Last Updated: Wednesday, September 18, 2013
Bookmark and Share
Eshmuno® A is a rigid, high capacity, acid and alkaline resistant Protein A affinity chromatography media.

Merck Millipore has introduced two additions to the Company's comprehensive chromatography portfolio to further accelerate downstream purification and improve process efficiency.

Eshmuno® A is a rigid, high capacity, acid and alkaline resistant Protein A affinity chromatography media for the purification of monoclonal antibodies and other Fc-containing proteins.

Higher binding capacities offered by Eshmuno® A media in comparison with other commercially available Protein A media delivers increased productivity and lower costs.

Eshmuno® A media can be cleaned and sanitized under acid and/or alkaline conditions while maintaining high dynamic binding capacity at high flow rates with no significant change in product purity.

In addition, the media offers an orthogonal solution for aggregate removal at both the front and tail ends of the elution peak from the Protein A column. This property of the Eshmuno® A media is advantageous in reducing the burden of subsequent chromatography steps typically used in the purification of Fc-containing proteins.

"Optimizing the particle size and pore size of the Eshmuno® base matrix along with the immobilization of our proprietary ligand enables a significant increase in dynamic binding capacity," states David Beattie, Ph.D., head Biopharm Process Solutions R&D, Merck Millipore.

Beattie continued, "This allows for higher loading of the Fc-containing protein being purified, maximizing column throughput and improving process economics. The ability to increase capacity and throughput with the Eshmuno® A media also allows our customers to more effectively process the high titers coming from upstream processing."

Chromabolt™ prepacked, pre-validated chromatography columns, available with a range of Merck Millipore chromatography resins, are designed for early clinical stage manufacturing.

Pre-validation indicates the columns meet bioburden, endotoxin, HETP and asymmetry specification for the resin. Offered in 3 sizes - 10, 20 and 32 cm i.d. - Chromabolt™ prepacked columns eliminate laborious packing and equipment cleaning.

The columns are currently available packed with Fractogel® SO3, Fractogel® TMAE HiCap, and Eshmuno® S resins. Going forward, additional resins will be made available in the Chromabolt™ format.

The prepacked columns are compatible with all currently available chromatography systems and connectors, have easily accessible inlets and outlets, and offer faster set-up times compared to traditional columns. Ergonomic and easily transportable by a single person, the 20 cm and 32 cm sizes are on wheels.

"Downstream processes must become faster, more lean, and cost-effective," notes Vin Donovan, head of Biopharm Process Solutions business field, Merck Millipore. "With Chromabolt™ prepacked columns, we help customers accelerate pilot and early stage clinical scale manufacturing and lower their costs by eliminating manual packing and equipment cleaning."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novel Mechanism for Activation of SIRT1
Assay format allows for simple, sensitive detection of sirtuin activity on any desired substrate.
Wednesday, April 24, 2013
Merck Millipore Announces New Genomic Biomarker Services
Genetic and epigenetic technologies added to established CRO services for biomarker development, validation and testing.
Wednesday, December 05, 2012
Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
Enables accelerated process development and production of proteins/monoclonal antibodies.
Friday, September 21, 2012
Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos